Meeting
2020 ASCO Virtual Scientific Program
Predictor of trastuzumab-induced cardiotoxicity in breast cancer (BC) patients: HER2/neu 655 polymorphisms, biochemical and clinical features.
Authors
Isabel Blancas
Oncology Department, San Cecilio University Hospital, Granada, Spain
Isabel Blancas , Celia Gómez , Francisco Javier Martín-Pérez , Jose Manuel Garrido , Fernando Rodríguez-Serrano
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Biologic Correlates
Citation
J Clin Oncol 38: 2020 (suppl; abstr 1033)
DOI
10.1200/JCO.2020.38.15_suppl.1033
Abstract #
1033
Poster Bd #
118
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Impact of body mass index (BMI) and weight change after treatment in patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Secondary analysis of the ALTTO BIG 2-06 trial.
First Author: Samuel Martel
Poster
2012 ASCO Annual Meeting
The PERSEPHONE trial: Duration of trastuzumab with chemotherapy in women with HER2-positive early breast cancer.
First Author: Helena Margaret Earl
Poster
2016 ASCO Annual Meeting
Improved outcomes in stage I HER2 positive breast cancer patients treated with trastuzumab and chemotherapy.
First Author: Shruti Rakesh Tiwari
Poster
2016 ASCO Annual Meeting
Benefit of adjuvant chemotherapy and/or trastuzumab in T1ab node-negative human epidermal growth factor receptor 2–positive breast carcinomas: Results of a national multi-institutional study.
First Author: Alexandre de Nonneville